This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
6-APDB: Difference between revisions
>Unity m Text replacement - "General formula" to "Generic structure" |
>White m Text replacement - "{| |- | 17px''Main articles: Research chemicals § Toxicity and harm potential'' ''&'' ''Responsible use § Hallucinogens'' |}" to "{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}" |
||
| Line 113: | Line 113: | ||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
{| | {{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}} | ||
Due to only having a short history of human use, the toxicity and harm potential is not exactly known. Due to its similarity to MDMA, it is likely that the administration of repeated or high dosages of 6-APDB can be neurotoxic and cardiotoxic<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref> in some form. | Due to only having a short history of human use, the toxicity and harm potential is not exactly known. Due to its similarity to MDMA, it is likely that the administration of repeated or high dosages of 6-APDB can be neurotoxic and cardiotoxic<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref> in some form. | ||
